Endo International - ENDP Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0 (0.00%)
Get New Endo International Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ENDP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ENDP

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Endo International in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for ENDP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Endo International. This rating has held steady since April 2023, when it changed from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/19/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/9/2022BMO Capital MarketsLower Target$4.00 ➝ $2.00
5/9/2022BarclaysLower Target$2.00 ➝ $1.00
5/6/2022Piper SandlerDowngradeNeutral ➝ Underweight$3.00 ➝ $1.00
3/9/2022CitigroupLower TargetBuy$11.00 ➝ $6.00
3/3/2022BMO Capital MarketsLower Target$8.00 ➝ $4.00
3/2/2022Piper SandlerLower TargetNeutral$5.00 ➝ $3.00
3/2/2022BarclaysDowngradeEqual Weight ➝ Underweight$5.00 ➝ $2.00
12/16/2021BarclaysLower TargetEqual Weight$7.00 ➝ $5.00
8/31/2021Piper SandlerDowngradeOverweight ➝ Neutral$10.00 ➝ $3.00
8/9/2021Royal Bank of CanadaLower TargetSector Perform$6.00 ➝ $5.00
5/17/2021CitigroupBoost TargetBuy$10.00 ➝ $11.00
4/7/2021Royal Bank of CanadaInitiated CoverageSector Perform$7.00
3/8/2021BarclaysBoost TargetPositive ➝ Equal Weight$6.00 ➝ $7.00
3/4/2021CitigroupLower Target$11.00 ➝ $10.00
3/3/2021Morgan StanleyBoost TargetUnderweight$5.00 ➝ $7.00
2/8/2021Leerink PartnersReiterated RatingMarket Perform
1/19/2021CitigroupBoost Target$7.00 ➝ $9.00
1/4/2021Piper SandlerBoost TargetOverweight$6.00 ➝ $12.00
11/12/2020Morgan StanleyBoost TargetUnderweight$3.00 ➝ $4.00
10/9/2020Piper SandlerBoost TargetOverweight$5.00 ➝ $6.00
7/27/2020The Goldman Sachs GroupInitiated CoverageSell$3.00
7/8/2020SunTrust BanksReiterated RatingBuy
6/11/2020Royal Bank of CanadaReiterated RatingHold$6.00
5/10/2020Royal Bank of CanadaReiterated RatingHold$6.00
4/24/2020CitigroupInitiated CoverageBuy$7.00
4/15/2020Piper SandlerLower TargetOverweight$7.00 ➝ $6.00
4/2/2020Royal Bank of CanadaReiterated RatingHold$6.00
4/2/2020Morgan StanleyLower TargetUnderweight$4.00 ➝ $3.00
(Data available from 3/21/2020 forward)

News Sentiment Rating

0.67 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
8/23/2024
  • 9 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
9/22/2024
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/22/2024
  • 5 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/21/2024
  • 8 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 4 very negative mentions
12/21/2024
  • 5 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/20/2025
  • 10 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
2/19/2025
  • 14 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
3/21/2025

Current Sentiment

  • 14 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Endo International logo
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.45
Low: $0.28
High: $0.75

52 Week Range

Now: N/A

Volume

9,967 shs

Average Volume

28,192,664 shs

Market Capitalization

$141 thousand

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.15

Frequently Asked Questions

What sell-side analysts currently cover shares of Endo International?

The following Wall Street research analysts have issued reports on Endo International in the last twelve months: StockNews.com.
View the latest analyst ratings for ENDP.

What is the current price target for Endo International?

0 Wall Street analysts have set twelve-month price targets for Endo International in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Endo International in the next year.
View the latest price targets for ENDP.

What is the current consensus analyst rating for Endo International?

Endo International currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ENDP.

What other companies compete with Endo International?

How do I contact Endo International's investor relations team?

Endo International's physical mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company's listed phone number is (531) 268-2000 and its investor relations email address is [email protected]. The official website for Endo International is www.endo.com. Learn More about contacing Endo International investor relations.